deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00004063

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

A Phase I-II Clinical Trial of Cisplatin (Platinol) Followed by Gemcitabine HCl (Gemzar) in Combination With Mild, Fever-Range Whole Body Hyperthermia (LL-WBH) at 40C in Patients With Advanced Malignancies

Sponsor: The University of Texas Health Science Center, Houston

Updated 6 times since 2017 Last updated: Apr 29, 2009 Started: Aug 31, 1999 Primary completion: Nov 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is ongoing. The trial is conducted by The University of Texas Health Science Center, Houston and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown StatusUnknown · Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1_PHASE2

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE1_PHASE2

    First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The University of Texas Health Science Center, Houston
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations